Home > Healthcare > Pharmaceuticals > Finished Drug Form > Regenerative Medicine Market

Regenerative Medicine Market Share

Report ID: GMI4571
Published Date: Sep 2023
Report Format: PDF

Download Free Sample

Regenerative Medicine Market Share

The key players in the regenerative medicine market are :

Novartis AG
Amgen, Inc.
Bristol Myers Squibb
BLUEBIRD BIO
GC Pharma
GlaxoSmithKline plc
ANTEROGEN
BIOSOLUTIONS
TERUMO BCT
AVITA MEDICAL
Smith and Nephew
ORGANOGENESIS

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global regenerative medicine industry was worth USD 52.3 billion in 2022 and is projected to grow at CAGR of 20.4% through 2032, driven by the increasing product development activities and expanding clinical applications.

Musculoskeletal segment accounted for a major market share of 31.6% in 2022, backed by the increasing prevalence of musculoskeletal diseases such as osteoarthritis, rheumatoid arthritis, and several orthopedic disorders.

North America regenerative medicines market accounted for a revenue share of 45.5% in 2022 and will continue growth over 2023-2032, favored by the increasing adoption of innovative treatment therapies along with growing prevalence of chronic diseases.

Novartis AG, Amgen, Inc., Bristol Myers Squibb, BLUEBIRD BIO, GC Pharma, GlaxoSmithKline plc, ANTEROGEN, BIOSOLUTIONS, TERUMO BCT, AVITA MEDICAL, Smith and Nephew, and ORGANOGENESIS.